Cou­pling mR­NA with tR­NA and new de­liv­ery tech, MPM and Or­biMed help birth new $80M biotech in­to a slowed down world

Part­ners at MPM and Or­biMed were hop­ing David Lock­hart could help them with due dili­gence when they brought him and his team at Tran­scrip­Tx in to look at a tiny up­start spun out of the Uni­ver­si­ty of Texas South­west­ern Med­ical Cen­ter in Dal­las. Dubbed Re­Code Ther­a­peu­tics, it was de­vel­op­ing a lipid nanopar­ti­cle (LNP) de­liv­ery plat­form for var­i­ous ge­net­ic med­i­cines, with a lead pro­gram in cys­tic fi­bro­sis backed by the CF Foun­da­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER